Clinical Evidence: How Wegovy and Mounjaro Compare in UK Studies
Wegovy and Mounjaro Dose Comparison: Understanding the Clinical Evidence
When evaluating Wegovy and Mounjaro dose comparison for weight management, UK patients benefit from robust clinical trial data demonstrating both treatments' effectiveness alongside reduced-calorie diet and increased physical activity. The landmark STEP trials for Wegovy showed participants achieved approximately 15% average weight loss at 68 weeks, with STEP 3 demonstrating ~16% weight reduction when combined with intensive behavioural therapy (Wilding et al., NEJM, 2021). Mounjaro's SURMOUNT trials revealed similar efficacy patterns, though direct head-to-head comparisons aren't available due to different trial designs and patient populations.
Both prescription-only medicines work through distinct mechanisms that influence their dosing strategies and patient outcomes. Wegovy's once-weekly semaglutide injection targets GLP-1 receptors specifically, promoting satiety and reducing appetite through natural hormone mimicry. Mounjaro combines GIP and GLP-1 receptor activation, creating a dual pathway approach that may offer different benefits for individual patients requiring structured weight management support.
Wegovy and Mounjaro Dose Escalation: Pricing and Value Comparison
Understanding Wegovy and Mounjaro dose comparison includes evaluating the financial commitment for each treatment pathway in the UK. Wegovy follows a mandatory five-stage escalation: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and 2.4mg maintenance (£209.99). Our Intro Trio bundle provides the first three doses for £299.99, ensuring seamless progression through initial treatment phases. New customers receive FIRST40 discount code benefits, while returning patients access DOSE25 savings at checkout.
Mounjaro requires similar dose escalation but follows a different schedule with varying price points reflecting its dual-agonist formulation. Both treatments represent significant monthly investments, making bundle options particularly valuable for maintaining consistent supply without repeated ordering. EverydayMeds' GPhC-registered pharmacy (#9012878) provides both medications with identical clinical assessment standards and next-day delivery protocols.
STEP Trial Results: Wegovy's Evidence-Based Weight Loss Outcomes
The STEP clinical programme provides compelling evidence for Wegovy's effectiveness in UK patient populations seeking sustainable weight management. STEP 1 demonstrated ~15% average weight loss at 68 weeks compared to ~2.4% with placebo, while STEP 5 confirmed ~15.2% weight reduction sustained at two years with continued treatment. These results occurred alongside reduced-calorie diet and increased physical activity, emphasising the importance of comprehensive lifestyle modifications.
Recent SELECT trial data adds cardiovascular benefits to Wegovy's profile, showing 20% reduction in major cardiovascular events (HR 0.80) among participants with established cardiovascular disease. This evidence supports Wegovy's role beyond weight management, potentially benefiting patients with multiple comorbidities requiring integrated medical supervision and ongoing monitoring.
How Wegovy Works: GLP-1 Mechanism for Appetite Control
Wegovy's semaglutide formulation mimics glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates appetite and food intake through brain-gut communication pathways. When administered via once-weekly FlexTouch pen injection, semaglutide binds to GLP-1 receptors in the hypothalamus, promoting feelings of fullness and reducing food cravings between meals. This mechanism may help patients achieve portion control more effectively than dietary modifications alone. The treatment works by slowing gastric emptying, extending satiety duration after eating, and potentially reducing hedonic food drive through reward pathway modulation. Clinical studies suggest these effects contribute to the sustained weight loss observed in STEP trial participants receiving Wegovy alongside behavioural interventions. Understanding this mechanism helps patients set realistic expectations about how Wegovy may support their weight management journey when combined with reduced-calorie diet and increased physical activity.
Ordering Process: Getting Wegovy Through EverydayMeds
Accessing Wegovy through our GPhC-registered online pharmacy requires completing a comprehensive 3-minute clinical assessment covering medical history, current medications, and weight management goals. Our qualified prescribers review each application within standard 3 working days, with express 24-hour review available for urgent cases. Once approved, we dispatch Wegovy pens via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity throughout transit. The prescription-only medicine arrives in discrete packaging with detailed injection instructions, dose escalation guidance, and access to our clinical support team for ongoing questions. Payment processing includes automatic application of FIRST40 (new customers) or DOSE25 (returning customers) discount codes at checkout, ensuring transparent pricing without hidden fees or subscription commitments.
Storage and Practical Considerations: Wegovy vs Mounjaro Comparison
Wegovy offers significant storage advantages over Mounjaro for UK patients requiring travel flexibility or inconsistent refrigeration access. While both medications require initial refrigerated storage at 2-8°C, Wegovy maintains stability for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. This extended room temperature stability proves particularly valuable for business travel, holidays, or temporary accommodation where refrigeration access may be limited. The FlexTouch pen delivery system provides accurate dosing with minimal injection discomfort, featuring ultra-fine needles and automatic dose selection to reduce user error during self-administration. Dose escalation cannot be rushed or skipped, requiring patients to complete each four-week phase before progressing to higher doses, ensuring optimal tolerance and minimising potential side effects throughout treatment.
UK-Specific Wegovy and Mounjaro Dose Comparison Factors
British patients evaluating Wegovy and Mounjaro dose comparison benefit from NICE guidance (TA875) recommending Wegovy alongside specialist weight management support for eligible individuals. This endorsement reflects comprehensive evidence review and cost-effectiveness analysis specific to UK healthcare contexts. NHS availability remains limited, making private prescription options through registered pharmacies like EverydayMeds essential for timely access.
Both treatments require ongoing medical supervision due to MHRA additional monitoring status (Black Triangle ▼), particularly during dose escalation phases where gastrointestinal side effects may occur. UK prescribers emphasise the importance of gradual dose increases and consistent administration timing to optimise treatment outcomes while minimising adverse effects that could impact long-term adherence.
Making Your Choice: Wegovy and Mounjaro Treatment Selection
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your medical history, lifestyle requirements, and weight management objectives. Consider factors including storage convenience, injection frequency preferences, and individual response to previous weight loss attempts when discussing options during clinical assessment. Our experienced clinical team provides personalised guidance based on current evidence and individual patient characteristics, ensuring you receive the most appropriate treatment recommendation.
Start your weight management journey today by completing our confidential online assessment, with treatments available from £79.99 using discount codes FIRST40 (new customers) or DOSE25 (returning patients) applied automatically at checkout. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical evaluation and access genuine prescription-only medicines through our GPhC-registered pharmacy service. Weight management represents a long-term commitment, and we're here to support your success with professional guidance, convenient delivery, and ongoing clinical oversight throughout your treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
